Sangamo Therapeutics Inc (NAS:SGMO)
$ 2.16 0.42 (24.14%) Market Cap: 449.76 Mil Enterprise Value: 363.62 Mil PE Ratio: 0 PB Ratio: 19.64 GF Score: 42/100

Q1 2020 Sangamo Therapeutics Inc Earnings Call Transcript

May 11, 2020 / 09:00PM GMT
Release Date Price: $9.06 (+4.14%)
Operator

Good afternoon, and welcome to the Sangamo Therapeutics Teleconference to discuss first quarter 2020 financial results. This call is being recorded.

I will now pass you over to the coordinator of this event, McDavid Stilwell, Senior Vice President of Corporate Communications and Investor Relations.

McDavid Stilwell
Sangamo Therapeutics, Inc. - SVP of Corporate Communications & IR

Good afternoon, and thank you for joining us today. With me this afternoon on this call are several members of the Sangamo senior management team, including Sandy Macrae, Chief Executive Officer; Sung Lee, Chief Financial Officer; Stéphane Boissel, Head of Corporate Strategy; Adrian Woolfson, Head of Research and Development; Mark McClung, Chief Business Officer; and Bettina Cockroft, Chief Medical Officer.

Slides from our corporate presentation can be found at our website, sangamo.com, under the Investors and Media section in the Events and Presentations page.

This call includes forward-looking statements regarding Sangamo's current expectations.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot